A Randomized, Double-blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of RT001 in Patients With Friedreich's Ataxia

Trial Profile

A Randomized, Double-blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of RT001 in Patients With Friedreich's Ataxia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs RT 001 (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Retrotope
  • Most Recent Events

    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 03 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 16 Sep 2016 Results published in a Retrotope media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top